E
NovoCure Limited
NVCR
$16.50
$0.422.61%
E
Sell
3/17/2025Downgrade
NovoCure Limited (NVCR) was downgraded to E+ from D- on 3/17/2025 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 133.26% from $10.38M to -$3.45M, earnings per share declined from -$0.2824 to -$0.6078, and EBIT declined 94.29% from -$32.09M to -$62.35M.
NovoCure Limited (NVCR) was downgraded to E+ from D- on 3/17/2025 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 133.26% from $10.38M to -$3.45M, earnings per share declined from -$0.2824 to -$0.6078, and EBIT declined 94.29% from -$32.09M to -$62.35M.
D
Sell
1/28/2025Upgraded
NovoCure Limited (NVCR) was upgraded to D- from E+ on 1/28/2025 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 703.26% from -$1.72M to $10.38M, earnings per share increased from -$0.31 to -$0.2824, and EBIT increased 4.51% from -$33.61M to -$32.09M.
NovoCure Limited (NVCR) was upgraded to D- from E+ on 1/28/2025 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 703.26% from -$1.72M to $10.38M, earnings per share increased from -$0.31 to -$0.2824, and EBIT increased 4.51% from -$33.61M to -$32.09M.
E
Sell
6/7/2023Downgrade
NovoCure Limited (NVCR) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index.
NovoCure Limited (NVCR) was downgraded to E+ from D- on 6/7/2023 due to a decline in the volatility index.
D
Sell
5/23/2023Upgraded
NovoCure Limited (NVCR) was upgraded to D- from E+ on 5/23/2023 due to an increase in the total return index and volatility index.
NovoCure Limited (NVCR) was upgraded to D- from E+ on 5/23/2023 due to an increase in the total return index and volatility index.
E
Sell
5/8/2023Downgrade
NovoCure Limited (NVCR) was downgraded to E+ from D- on 5/8/2023 due to a noticeable decline in the solvency index, total return index and growth index. Operating cash flow declined 351.23% from -$3.71M to -$16.73M, EBIT declined 42.21% from -$42.37M to -$60.25M, and earnings per share declined from -$0.3552 to -$0.5022.
NovoCure Limited (NVCR) was downgraded to E+ from D- on 5/8/2023 due to a noticeable decline in the solvency index, total return index and growth index. Operating cash flow declined 351.23% from -$3.71M to -$16.73M, EBIT declined 42.21% from -$42.37M to -$60.25M, and earnings per share declined from -$0.3552 to -$0.5022.
D
Sell
4/13/2023Upgraded
NovoCure Limited (NVCR) was upgraded to D- from E+ on 4/13/2023 due to an increase in the total return index and volatility index.
NovoCure Limited (NVCR) was upgraded to D- from E+ on 4/13/2023 due to an increase in the total return index and volatility index.
E
Sell
3/24/2023Downgrade
NovoCure Limited (NVCR) was downgraded to E+ from D- on 3/24/2023 due to a decline in the volatility index and total return index.
NovoCure Limited (NVCR) was downgraded to E+ from D- on 3/24/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
NovoCure Limited (NVCR) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 116.53% from $22.42M to -$3.71M, EBIT declined 72.15% from -$24.61M to -$42.37M, and earnings per share declined from -$0.2534 to -$0.3552.
NovoCure Limited (NVCR) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index, solvency index and total return index. Operating cash flow declined 116.53% from $22.42M to -$3.71M, EBIT declined 72.15% from -$24.61M to -$42.37M, and earnings per share declined from -$0.2534 to -$0.3552.
D
Sell
2/23/2023Upgraded
NovoCure Limited (NVCR) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
NovoCure Limited (NVCR) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index, volatility index and valuation index.
D
Sell
2/8/2023Downgrade
NovoCure Limited (NVCR) was downgraded to D- from D on 2/8/2023 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 10.7% from -$24.01M to -$26.58M.
NovoCure Limited (NVCR) was downgraded to D- from D on 2/8/2023 due to a substantial decline in the efficiency index, total return index and volatility index. Net income declined 10.7% from -$24.01M to -$26.58M.
D
Sell
8/31/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D from D+ on 8/31/2021 due to a large decline in the total return index and volatility index.
NovoCure Limited (NVCR) was downgraded to D from D+ on 8/31/2021 due to a large decline in the total return index and volatility index.
D
Sell
8/16/2021Upgraded
NovoCure Limited (NVCR) was upgraded to D+ from D on 8/16/2021 due to a noticeable increase in the total return index and valuation index.
NovoCure Limited (NVCR) was upgraded to D+ from D on 8/16/2021 due to a noticeable increase in the total return index and valuation index.
D
Sell
7/30/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D from D+ on 7/30/2021 due to a large decline in the total return index and efficiency index. Net income declined 254.68% from -$4.13M to -$14.64M.
NovoCure Limited (NVCR) was downgraded to D from D+ on 7/30/2021 due to a large decline in the total return index and efficiency index. Net income declined 254.68% from -$4.13M to -$14.64M.
D
Sell
7/29/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 7/29/2021 due to a noticeable decline in the total return index and volatility index.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 7/29/2021 due to a noticeable decline in the total return index and volatility index.
C
Hold
7/1/2021Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 7/1/2021 due to an increase in the total return index.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 7/1/2021 due to an increase in the total return index.
D
Sell
6/16/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 6/16/2021 due to a decline in the volatility index and valuation index.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 6/16/2021 due to a decline in the volatility index and valuation index.
C
Hold
6/1/2021Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 6/1/2021 due to an increase in the volatility index.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 6/1/2021 due to an increase in the volatility index.
D
Sell
5/17/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 5/17/2021 due to a substantial decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.0403 to -$0.0402, net income declined 183.95% from $4.92M to -$4.13M, and EBIT declined 100.7% from $12.5M to -$88.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 5/17/2021 due to a substantial decline in the growth index, solvency index and efficiency index. Earnings per share declined from $0.0403 to -$0.0402, net income declined 183.95% from $4.92M to -$4.13M, and EBIT declined 100.7% from $12.5M to -$88.
C
Hold
4/20/2021Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 4/20/2021 due to a major increase in the total return index.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 4/20/2021 due to a major increase in the total return index.
D
Sell
4/5/2021Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 4/5/2021 due to a major decline in the total return index.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 4/5/2021 due to a major decline in the total return index.
C
Hold
3/8/2021Downgrade
NovoCure Limited (NVCR) was downgraded to C- from C on 3/8/2021 due to a decline in the total return index and efficiency index. Net income declined 47.04% from $9.28M to $4.92M.
NovoCure Limited (NVCR) was downgraded to C- from C on 3/8/2021 due to a decline in the total return index and efficiency index. Net income declined 47.04% from $9.28M to $4.92M.
C
Hold
10/28/2020Upgraded
NovoCure Limited (NVCR) was upgraded to C from C- on 10/28/2020 due to a significant increase in the total return index.
NovoCure Limited (NVCR) was upgraded to C from C- on 10/28/2020 due to a significant increase in the total return index.
C
Hold
9/28/2020Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 9/28/2020 due to an increase in the total return index and volatility index.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 9/28/2020 due to an increase in the total return index and volatility index.
D
Sell
8/21/2020Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 8/21/2020 due to a decline in the total return index and valuation index.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 8/21/2020 due to a decline in the total return index and valuation index.
C
Hold
7/31/2020Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 7/31/2020 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 551.05% from $1.96M to $12.74M, EBIT increased 297.22% from -$3.38M to $6.67M, and total revenue increased 13.84% from $101.83M to $115.93M.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 7/31/2020 due to a large increase in the growth index, efficiency index and total return index. Operating cash flow increased 551.05% from $1.96M to $12.74M, EBIT increased 297.22% from -$3.38M to $6.67M, and total revenue increased 13.84% from $101.83M to $115.93M.
D
Sell
5/20/2020Downgrade
NovoCure Limited (NVCR) was downgraded to D+ from C- on 5/20/2020 due to a major decline in the growth index, volatility index and total return index. EBIT declined 804.38% from $480 to -$3.38M, operating cash flow declined 71.89% from $6.96M to $1.96M, and earnings per share declined from $0.0404 to $0.0396.
NovoCure Limited (NVCR) was downgraded to D+ from C- on 5/20/2020 due to a major decline in the growth index, volatility index and total return index. EBIT declined 804.38% from $480 to -$3.38M, operating cash flow declined 71.89% from $6.96M to $1.96M, and earnings per share declined from $0.0404 to $0.0396.
C
Hold
3/3/2020Downgrade
NovoCure Limited (NVCR) was downgraded to C- from C on 3/3/2020 due to a substantial decline in the total return index and growth index. EBIT declined 87.55% from $3.86M to $480, and operating cash flow declined 53.3% from $14.91M to $6.96M.
NovoCure Limited (NVCR) was downgraded to C- from C on 3/3/2020 due to a substantial decline in the total return index and growth index. EBIT declined 87.55% from $3.86M to $480, and operating cash flow declined 53.3% from $14.91M to $6.96M.
C
Hold
12/24/2019Upgraded
NovoCure Limited (NVCR) was upgraded to C from C- on 12/24/2019 due to a noticeable increase in the volatility index, efficiency index and solvency index. Net income increased 251.97% from -$1.27M to $1.93M, debt to equity declined from 0.96 to 0.81, and total capital increased 9.76% from $323.78M to $355.37M.
NovoCure Limited (NVCR) was upgraded to C from C- on 12/24/2019 due to a noticeable increase in the volatility index, efficiency index and solvency index. Net income increased 251.97% from -$1.27M to $1.93M, debt to equity declined from 0.96 to 0.81, and total capital increased 9.76% from $323.78M to $355.37M.
C
Hold
8/15/2019Upgraded
NovoCure Limited (NVCR) was upgraded to C- from D+ on 8/15/2019 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 310.1% from -$4.32M to $9.07M, EBIT increased 119.55% from -$6.12M to $1.2M, and earnings per share increased from -$0.1281 to -$0.0132.
NovoCure Limited (NVCR) was upgraded to C- from D+ on 8/15/2019 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 310.1% from -$4.32M to $9.07M, EBIT increased 119.55% from -$6.12M to $1.2M, and earnings per share increased from -$0.1281 to -$0.0132.
D
Sell
6/7/2019Upgraded
NovoCure Limited (NVCR) was upgraded to D+ from D on 6/7/2019 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 26.41% from -$8.31M to -$6.12M, earnings per share increased from -$0.1679 to -$0.1281, and total revenue increased 5.22% from $69.67M to $73.31M.
NovoCure Limited (NVCR) was upgraded to D+ from D on 6/7/2019 due to a significant increase in the total return index, growth index and solvency index. EBIT increased 26.41% from -$8.31M to -$6.12M, earnings per share increased from -$0.1679 to -$0.1281, and total revenue increased 5.22% from $69.67M to $73.31M.
D
Sell
10/27/2017Upgraded
NovoCure Limited (NVCR) was upgraded to D from D- on 10/27/2017 due to a significant increase in the total return index, volatility index and solvency index.
NovoCure Limited (NVCR) was upgraded to D from D- on 10/27/2017 due to a significant increase in the total return index, volatility index and solvency index.
D
Sell
12/7/2016Upgraded
NovoCure Limited (NVCR) was upgraded to D- from E+ on 12/7/2016 due to an increase in the valuation index.
NovoCure Limited (NVCR) was upgraded to D- from E+ on 12/7/2016 due to an increase in the valuation index.
E
Sell
11/22/2016Downgrade
NovoCure Limited (NVCR) was downgraded to E+ from D- on 11/22/2016 due to a noticeable decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.12 to 0.61.
NovoCure Limited (NVCR) was downgraded to E+ from D- on 11/22/2016 due to a noticeable decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.12 to 0.61.
D
Sell
3/11/2016Downgrade
NovoCure Limited (NVCR) was downgraded to D- from D on 3/11/2016 due to a large decline in the total return index, volatility index and valuation index.
NovoCure Limited (NVCR) was downgraded to D- from D on 3/11/2016 due to a large decline in the total return index, volatility index and valuation index.
D
Sell
3/1/2016Upgraded
NovoCure Limited (NVCR) was upgraded to D from E on 03/01/2016.
NovoCure Limited (NVCR) was upgraded to D from E on 03/01/2016.
E
Sell
2/23/2016Downgrade
NovoCure Limited (NVCR) was downgraded to E from D on 2/23/2016 due to a decline in the total return index.
NovoCure Limited (NVCR) was downgraded to E from D on 2/23/2016 due to a decline in the total return index.
D
Sell
2/22/2016Upgraded
NovoCure Limited (NVCR) was upgraded to D from E on 02/22/2016.
NovoCure Limited (NVCR) was upgraded to D from E on 02/22/2016.
E
Sell
2/19/2016Downgrade
NovoCure Limited (NVCR) was downgraded to E from D on 2/19/2016 due to a decline in the total return index.
NovoCure Limited (NVCR) was downgraded to E from D on 2/19/2016 due to a decline in the total return index.
D
Sell
2/8/2016Upgraded
NovoCure Limited (NVCR) was upgraded to D from E on 02/08/2016.
NovoCure Limited (NVCR) was upgraded to D from E on 02/08/2016.
E
Sell
2/1/2016Downgrade
NovoCure Limited (NVCR) was downgraded to E from D on 2/1/2016 due to a decline in the total return index and volatility index.
NovoCure Limited (NVCR) was downgraded to E from D on 2/1/2016 due to a decline in the total return index and volatility index.
D
Sell
1/25/2016Upgraded
NovoCure Limited (NVCR) was upgraded to D from E on 01/25/2016.
NovoCure Limited (NVCR) was upgraded to D from E on 01/25/2016.
E
Sell
1/22/2016Downgrade
NovoCure Limited (NVCR) was downgraded to E from D on 1/22/2016 due to a substantial decline in the volatility index.
NovoCure Limited (NVCR) was downgraded to E from D on 1/22/2016 due to a substantial decline in the volatility index.
D
Sell
12/28/2015None
NovoCure Limited (NVCR) was downgraded to D from U on 12/28/2015.
NovoCure Limited (NVCR) was downgraded to D from U on 12/28/2015.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
